Skip to content
DataLookout
Menu

KIEONCT05977907

Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 10 versions: 7 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Primary completion pushed from Oct 16, 2026 to Dec 2026
  2. Notable Eligibility criteria expanded, about 33 words Show 4 more changesShow less
    • Enrollment closed, study ongoing
    • Secondary endpoints: details revised at 1 of 5 entries
    • Site details revised at 5 of 5 sites
    • Collaborators: details revised at 1 of 2 entries
  3. Notable Enrollment target: 15 to 30v8
  4. Minor Start date changed from estimate of Dec 1, 2023 to Dec 14, 2023v4
  5. Notable Start date: Oct 16, 2023 to Dec 1, 2023v3
  6. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Start date: Sep 1, 2023 to Oct 16, 2023
    • Study sites: 1 to 5
    • Primary completion date: Sep 1, 2026 to Oct 16, 2026
    • Study completion date: Sep 1, 2028 to Oct 16, 2028
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Pathologic Treatment Response rate
Timeframe: From neoadjuvant therapy to surgical resection, up to 6 weeks

Secondary (5)

Major Pathologic Response
Disease progression
Overall survival
Overall Safety
ctDNA in comparison to other neoadjuvant treatments

Arms and interventions

Single CohortExperimental

Neoadjuvant Pembrolizumab ( 400mg IV infusion x1) + IO102-103 ( Subcutaneous injection weekly x6) Adjuvant Pembrolizumab ( 400 mg IV infusion Every 6 weeks x8) + IO102-103 ( Subcutaneous injection every 3 week x6 then every 6 weeks x5)

Drugs: Pembrolizumab, IO102-103

Sites

5 sites in 1 country